Gloucester Pharmaceuticals today announced that positive data from a Phase 2 trial of romidepsin conducted by the U.S. National Cancer Institute (NCI) were presented at the 13th Congress of the European Hematology Association in Copenhagen, Denmark.

Gloucester Pharmaceuticals today announced that its late-stage product candidate, romidepsin, was the subject of a podium presentation entitled "International Trial Confirms Romidpesin Efficacy in Refractory CTCL Patients" at the 10th International Conference on Malignant Lymphoma, held in Lugano, Switzerland.

Gloucester Pharmaceuticals today announced results from a Phase 1 study of romidepsin in combination with gemcitabine in patients with solid tumors.

Gloucester Pharmaceuticals has reported positive results from a Phase IIb registration trial of romidepsin in patients with advanced cutaneous T-cell lymphoma.

Gloucester Pharmaceuticals today announced the presentation of positive data from a Phase 2b registration trial of romidepsin in patients with advanced cutaneous T-cell lymphoma (CTCL).